Free Trial

MaxCyte (LON:MXCT) Stock Price Crosses Below 50 Day Moving Average - What's Next?

MaxCyte logo with Medical background

Shares of MaxCyte, Inc. (LON:MXCT - Get Free Report) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 180.07 ($2.42) and traded as low as GBX 152.96 ($2.06). MaxCyte shares last traded at GBX 165 ($2.22), with a volume of 18,641 shares changing hands.

MaxCyte Stock Up 3.1%

The company has a debt-to-equity ratio of 8.59, a current ratio of 9.81 and a quick ratio of 14.38. The stock has a fifty day moving average price of GBX 180.07 and a two-hundred day moving average price of GBX 260.88. The company has a market cap of £217.81 million, a P/E ratio of -6.05 and a beta of 1.13.

About MaxCyte

(Get Free Report)

MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in MaxCyte Right Now?

Before you consider MaxCyte, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.

While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Congress Bought This Stock at the Bottom—Will You Miss It?
The Drone Industry Is About to 10X—Here’s How to Profit
Why AMD Stock Beats NVIDIA Right Now

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines